ºÝºÝߣ

ºÝºÝߣShare a Scribd company logo

Presentation Design for Medical Research Study

?
?
Tina Salacup
Tina Salacup

This document summarizes treatment options for iron deficiency anemia associated with gastrointestinal diseases. Oral iron therapy is commonly used but has side effects and low compliance due to gastrointestinal issues. Parenteral iron therapy provides advantages as iron is absorbed directly into the bloodstream, avoiding gastrointestinal absorption. A novel parenteral iron complex, ferric carboxymaltose, has a favorable safety profile and may be more effective than oral iron or older parenteral therapies for treating iron deficiency anemia linked to gastrointestinal conditions.

1 of 8
Treatmentof IronDeficiencyAnemia Associatedwith GastrointestinalDiseases Authors: Ulas D Bayraktar and Soley Bayraktar
Introduction o The GI tract is a common site of bleeding that may lead to iron deficiency anemia (IDA). o Treatment varies based on patient¡¯s signs & symptoms: Red blood cell transfusion & Oral iron preparations have side effects The bone marrow examination is not accurate o Raise awareness of parenteral iron therapies in the treatment of IDA linked with GI diseases, particularly inflammatory bowel diseases (IBDs).
Etiology
Methods Oral Iron Replacement Parenteral Iron Replacement o Asymptomatic and mildly symptomatic patients o Cannot be treated adequately with oral iron with IDA supplements due to severe GI side effects, etc. o Same efficacy & side effects between ferrous o Many clinicians have been reluctant due to the sulfate, ferrous gluconate, and ferrous fumarate rarely lethal hypersensitive reactions to high in a randomized, double blind study molecular weight iron dextran infusions o To avoid GI side effects and consequent non- o Ferric Carboxymaltose (FeCarb) is a novel compliance, oral iron should be started at a low parenteral iron complex with a favorable side dose once daily after meals effect profile
Results Parenteral therapy Oral iron therapy o May be more advantageous due to low iron absorption o High incidence of GI side effects (epigastric pain and from the GI tract & lower compliance to the oral diarrhea) that lead to discontinuation of therapy in up therapy. to 21% of patients o Useful in patients with moderate-severe active IBD o may worsen IBD as a result of non-absorbed iron- mediated toxic reactive oxygen species. o Quicker response o Does not have life-threatening side effects o More convenient for some patients
Cont.
Conclusion o As of Dec. 2009, FeCarb has not been evaluated by the Food and Drug Administration. o Novel parenteral iron preparations are safer than high molecular weight iron dextran & are more useful due to GI side effects of oral iron therapy. Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883127/?tool=pubmed
Presented by Christina Salacup

More Related Content

Presentation Design for Medical Research Study

  • 1. Treatmentof IronDeficiencyAnemia Associatedwith GastrointestinalDiseases Authors: Ulas D Bayraktar and Soley Bayraktar
  • 2. Introduction o The GI tract is a common site of bleeding that may lead to iron deficiency anemia (IDA). o Treatment varies based on patient¡¯s signs & symptoms: Red blood cell transfusion & Oral iron preparations have side effects The bone marrow examination is not accurate o Raise awareness of parenteral iron therapies in the treatment of IDA linked with GI diseases, particularly inflammatory bowel diseases (IBDs).
  • 4. Methods Oral Iron Replacement Parenteral Iron Replacement o Asymptomatic and mildly symptomatic patients o Cannot be treated adequately with oral iron with IDA supplements due to severe GI side effects, etc. o Same efficacy & side effects between ferrous o Many clinicians have been reluctant due to the sulfate, ferrous gluconate, and ferrous fumarate rarely lethal hypersensitive reactions to high in a randomized, double blind study molecular weight iron dextran infusions o To avoid GI side effects and consequent non- o Ferric Carboxymaltose (FeCarb) is a novel compliance, oral iron should be started at a low parenteral iron complex with a favorable side dose once daily after meals effect profile
  • 5. Results Parenteral therapy Oral iron therapy o May be more advantageous due to low iron absorption o High incidence of GI side effects (epigastric pain and from the GI tract & lower compliance to the oral diarrhea) that lead to discontinuation of therapy in up therapy. to 21% of patients o Useful in patients with moderate-severe active IBD o may worsen IBD as a result of non-absorbed iron- mediated toxic reactive oxygen species. o Quicker response o Does not have life-threatening side effects o More convenient for some patients
  • 7. Conclusion o As of Dec. 2009, FeCarb has not been evaluated by the Food and Drug Administration. o Novel parenteral iron preparations are safer than high molecular weight iron dextran & are more useful due to GI side effects of oral iron therapy. Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883127/?tool=pubmed